Movement Alert｜Gilead Sciences Rises 3.09% in Regular Trading, HSBC Upgrades Rating to Buy with $155 Target

Market Focus07-07 22:07

On July 7, Gilead Sciences rose 3.09% in regular trading, trading at $134.735/share, with turnover of $176 million. The move was catalyzed by HSBC's upgrade of the stock from Hold to Buy on July 6.

HSBC raised its target price from $133 to $155, implying approximately 15% upside from the current level. The upgrade appears to be the direct catalyst behind today's strength. FactSet consensus data shows the average analyst target price at $160.74 with an overall Buy rating, suggesting broader Wall Street confidence in the company's outlook.

The upgrade comes amid a period of significant corporate activity for Gilead, including the completion of its $7.8 billion Arcellx acquisition in late April, FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and a Q1 earnings beat of $2.03 adjusted EPS versus the $1.91 estimate. The company also raised full-year Yeztugo guidance to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135355399?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-07 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135355399","market":"us","top_or_hot":-1,"title":"Movement Alert｜Gilead Sciences Rises 3.09% in Regular Trading, HSBC Upgrades Rating to Buy with $155 Target","media":"Market Focus","content":"<p><p>On July 7, Gilead Sciences rose 3.09% in regular trading, trading at $134.735/share, with turnover of $176 million. The move was catalyzed by HSBC's upgrade of the stock from Hold to Buy on July 6.</p><p>HSBC raised its target price from $133 to $155, implying approximately 15% upside from the current level. The upgrade appears to be the direct catalyst behind today's strength. FactSet consensus data shows the average analyst target price at $160.74 with an overall Buy rating, suggesting broader Wall Street confidence in the company's outlook.</p><p>The upgrade comes amid a period of significant corporate activity for Gilead, including the completion of its $7.8 billion Arcellx acquisition in late April, FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and a Q1 earnings beat of $2.03 adjusted EPS versus the $1.91 estimate. The company also raised full-year Yeztugo guidance to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Gilead Sciences Rises 3.09% in Regular Trading, HSBC Upgrades Rating to Buy with $155 Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Gilead Sciences Rises 3.09% in Regular Trading, HSBC Upgrades Rating to Buy with $155 Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-07 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 7, Gilead Sciences rose 3.09% in regular trading, trading at $134.735/share, with turnover of $176 million. The move was catalyzed by HSBC's upgrade of the stock from Hold to Buy on July 6.</p><p>HSBC raised its target price from $133 to $155, implying approximately 15% upside from the current level. The upgrade appears to be the direct catalyst behind today's strength. FactSet consensus data shows the average analyst target price at $160.74 with an overall Buy rating, suggesting broader Wall Street confidence in the company's outlook.</p><p>The upgrade comes amid a period of significant corporate activity for Gilead, including the completion of its $7.8 billion Arcellx acquisition in late April, FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and a Q1 earnings beat of $2.03 adjusted EPS versus the $1.91 estimate. The company also raised full-year Yeztugo guidance to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GILD","symbol_name":"吉利德科学","start_time":0,"source_url":"","article_id":"1135355399","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135355399","pubTimestamp":1783433264,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 7, Gilead Sciences rose 3.09% in regular trading, trading at $134.735/share, with turnover of $176 million. The move was catalyzed by HSBC's upgrade of the stock from Hold to Buy on July...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GILD":"吉利德科学"},"translate_title":"动向提示|吉利德科学常规交易涨3.09%汇丰上调评级至买入目标155美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GILD":1},"content_text":"On July 7, Gilead Sciences rose 3.09% in regular trading, trading at $134.735/share, with turnover of $176 million. The move was catalyzed by HSBC's upgrade of the stock from Hold to Buy on July 6.HSBC raised its target price from $133 to $155, implying approximately 15% upside from the current level. The upgrade appears to be the direct catalyst behind today's strength. FactSet consensus data shows the average analyst target price at $160.74 with an overall Buy rating, suggesting broader Wall Street confidence in the company's outlook.The upgrade comes amid a period of significant corporate activity for Gilead, including the completion of its $7.8 billion Arcellx acquisition in late April, FDA priority review acceptance for its bictegravir/lenacapavir HIV combination therapy with an August 27 target action date, and a Q1 earnings beat of $2.03 adjusted EPS versus the $1.91 estimate. The company also raised full-year Yeztugo guidance to $1 billion from $800 million and total product sales guidance to $30.0-$30.4 billion.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135355399","isCrawlerRequest":true}